RNAZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Transcode Therapeutics Inc (RNAZ) is not a good buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, there are no positive trading signals, and the company's financial performance is weak with no significant growth trends. Additionally, there are no recent news catalysts or influential trading activity to support a bullish case.
The MACD is negatively expanding, RSI is neutral at 38.253, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels with support at 8.809 and resistance at 9.942. Overall, the technical outlook is bearish.
NULL identified. No recent news, no positive trading trends, and no significant insider or hedge fund activity.
Bearish technical indicators, weak financial performance with declining EPS (-96.02% YoY), and no significant trading signals or news catalysts.
In Q3 2025, the company reported zero revenue growth (0.00% YoY), a net income loss of -$4,856,051 (up 109.19% YoY), and a significant EPS decline (-96.02% YoY). Gross margin remains at 0%.
No analyst rating or price target changes available.
